EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges

Zuber Khan iD, Ghanshyam Das Gupta, Sidharth Mehan iD

Journal of Clinical Medicine · 26.06.2023 · 12 (13) · 4274

DOI: 10.3390/jcm12134274 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.06.2023. Verfasst von Zuber Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daejeon Institute of Science and Technology, Department of Science and Technology, Science and Engineering Research Board, Government of India, DST-SERB, CRG (Core Research Grant).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India’s treatment techniques vary. In addition, India’s population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition.

Schlagwörter

Stichwörter der Autor:innen

autoimmune reactionsbiomarkersdisease-modifying agentsmultiple sclerosisneurodegeneration

Autor:innen und Institutionen

  • Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India.
  • Department of Pharmaceutics, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India.

ORCID-Profile: Zuber Khan, Sidharth Mehan

Förderung

  • Daejeon Institute of Science and Technology
  • Department of Science and Technology, Science and Engineering Research Board, Government of India, DST-SERB, CRG (Core Research Grant)

Zitieren

APA

Khan, Z., Gupta, G. D., & Mehan, S. (2023). Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. Journal of Clinical Medicine, 12(13), 4274. https://doi.org/10.3390/jcm12134274

Vancouver

Khan Z, Gupta GD, Mehan S. Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. Journal of Clinical Medicine. 2023;12(13):4274. doi:10.3390/jcm12134274

BibTeX
@article{Khan2023,
  author = {Khan, Zuber and Gupta, Ghanshyam Das and Mehan, Sidharth},
  title = {Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {13},
  pages = {4274},
  doi = {10.3390/jcm12134274}
}
Kostenlos starten →